Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma, Kaposi 3Myeloproliferative Disorders 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Acquired Immunodeficiency Syndrome 2Plasmablastic Lymphoma 1Optic Nerve Glioma 1Neurofibromatosis 1 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Lymphoma, Primary Effusion 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Epstein-Barr Virus Infections 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1

Interventions

Vincristine 3Rituximab 3Prednisone 3Etoposide 3Doxorubicin 3Cyclophosphamide 3varlilumab 1prednylidene 1pomalidomide 1liposomal doxorubicin 1etoposide phosphate 1deltacortene 1Vorinostat 1Ultrasonography 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Endoscopy 1Electrocardiography 1Echocardiography 1Disulfides 1CT-P10 1Bronchoscopy 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Primary Effusion × pomalidomide × Clear all
NCT02228512 2018-08-31

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡